Excellent response to anti-CD38 therapy with daratumumab in a patient with severe refractory CANOMAD.

Elba Pascual-GoñiRoger ColletClara Tejada-IllaLorena Martín-Aguilar Marta Caballero-ÁvilaCinta LleixàSilvana NovelliJordi López-PardoAlbert Esquirol SanfeliuAnais MariscalYolanda Álvaro GargalloEugenia Martinez-HernandezDolores CochoLuis Antonio Querol-Gutiérrez

Published in: Journal of neurology, neurosurgery, and psychiatry (2024)

The first patient with aggressive treatment-refractory CANOMAD treated with daratumumab provides proof-of-principle evidence that daratumumab may be an effective treatment in IgM-related neuropathies.

Keyphrases

multiple myeloma
case report
stem cells
mesenchymal stem cells
early onset
newly diagnosed